Evogene Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Ofer Haviv
Chief executive officer
US$401.0k
Total compensation
| CEO salary percentage | 97.3% |
| CEO tenure | 19.3yrs |
| CEO ownership | n/a |
| Management average tenure | 2.2yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
Evogene unit files for EPA approval of bio-fungicide LAV.311 for fruit rots
Oct 12Evogene unit launches 2nd-gen medical cannabis products in Israel
Sep 21Lavie Bio appoints Guri Oron as CEO
Sep 14Evogene GAAP EPS of -$0.42 misses by $0.23, revenue of $0.55M beats by $0.33M
Aug 31Evogene regains compliance with Nasdaq's minimum bid price requirement
Aug 25Evogen stock rises after unit gets $10M investment from ICL under collaboration agreement
Aug 17Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus
Mar 22Evogene: Computational Biology Technology Hub; Focus On Canonic (Medical Cannabis)
Mar 03Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical Market
Sep 14Evogene: Bullish With Canonic's Entry Into Israeli Medical Cannabis Markets
Jun 16Evogene EPS beats by $0.01, beats on revenue
May 26Evogene unit - Canonic inks cultivation deal for medical cannabis varieties
Dec 23AgPlenus reaches a 'Lead' Stage in its mode-of-action herbicide program
Dec 15Evogene: Q3 Update And Upcoming Catalysts
Nov 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$401k | US$390k | -US$24m |
| Sep 30 2023 | n/a | n/a | -US$20m |
| Jun 30 2023 | n/a | n/a | -US$23m |
| Mar 31 2023 | n/a | n/a | -US$25m |
| Dec 31 2022 | US$464k | US$415k | -US$27m |
| Sep 30 2022 | n/a | n/a | -US$31m |
| Jun 30 2022 | n/a | n/a | -US$32m |
| Mar 31 2022 | n/a | n/a | -US$29m |
| Dec 31 2021 | US$530k | US$420k | -US$28m |
| Sep 30 2021 | n/a | n/a | -US$29m |
| Jun 30 2021 | n/a | n/a | -US$26m |
| Mar 31 2021 | n/a | n/a | -US$24m |
| Dec 31 2020 | US$592k | US$367k | -US$23m |
| Sep 30 2020 | n/a | n/a | -US$21m |
| Jun 30 2020 | n/a | n/a | -US$21m |
| Mar 31 2020 | n/a | n/a | -US$21m |
| Dec 31 2019 | US$538k | US$366k | -US$18m |
| Sep 30 2019 | n/a | n/a | -US$18m |
| Jun 30 2019 | n/a | n/a | -US$18m |
| Mar 31 2019 | n/a | n/a | -US$19m |
| Dec 31 2018 | US$517k | US$324k | -US$21m |
| Sep 30 2018 | n/a | n/a | -US$21m |
| Jun 30 2018 | n/a | n/a | -US$21m |
| Mar 31 2018 | n/a | n/a | -US$21m |
| Dec 31 2017 | US$649k | US$359k | -US$21m |
Compensation vs Market: Ofer's total compensation ($USD401.00K) is below average for companies of similar size in the US market ($USD670.12K).
Compensation vs Earnings: Ofer's compensation has been consistent with company performance over the past year.
CEO
Ofer Haviv (57 yo)
19.3yrs
Tenure
US$401,000
Compensation
Mr. Ofer Haviv, CPA, served as Interim Chief Executive Officer of Lavie Bio Ltd. since January 2023. He has been Chief Executive Officer and President of Evogene Limited since December 2004 and served as i...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & President | 19.3yrs | US$401.00k | no data | |
| Chief Product Officer | 2.7yrs | US$292.00k | 0% $ 0 | |
| Chief Executive Officer of AgPlenus Ltd | 2.3yrs | US$456.00k | no data | |
| Chief Executive Officer of Biomica Ltd | 6.3yrs | US$339.00k | 0% $ 0 | |
| Chief Executive Officer of Lavie Bio Ltd. | less than a year | US$606.00k | no data | |
| Chief Financial Officer | 2yrs | no data | 0% $ 0 | |
| Chief Technology Officer | 6.2yrs | US$299.00k | 0% $ 0 | |
| Head of Investor Relations | less than a year | no data | no data | |
| Vice President of Corporate Development | 2.2yrs | US$304.00k | 0% $ 0 | |
| Vice President of Human Resources | 2.3yrs | no data | no data | |
| Executive Vice President of Business Development | 1.8yrs | no data | 0% $ 0 | |
| Chief Executive Officer of Casterra Ag Ltd. | less than a year | no data | no data |
2.2yrs
Average Tenure
46.5yo
Average Age
Experienced Management: EVGN's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 2.4yrs | no data | 0% $ 0 | |
| Independent Director | 1.4yrs | no data | 0% $ 0 | |
| Independent Director | 18.9yrs | no data | 1.66% $ 571.3k | |
| Independent Chairperson of the Board | 7.7yrs | no data | 0% $ 0 | |
| Independent Director | 5.4yrs | no data | 0% $ 0 | |
| Chairman of Scientific Advisors | no data | no data | no data | |
| Independent Director | 5.2yrs | no data | 0% $ 0 | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | 2.3yrs | no data | no data |
5.2yrs
Average Tenure
62.5yo
Average Age
Experienced Board: EVGN's board of directors are considered experienced (5.2 years average tenure).